1. (ed.). Chronic Illness in the United States, Vol. 1. Cambridge, MA: Harvard University Press, 1957.
2. , (eds.) Principles and Practice of Screening for Disease [Public Health Paper No. 34]. Geneva: World Health Organization, 1968.
3. , , , et al. Evaluation of screening programmes for gynaecological cancer. Br J Cancer 1985;52:669–673.
4. , , , et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277–284.
5. , , , et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20–25.
6. , , . Cancer of the cervix, vagina, and vulva. In ., , (eds.) Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
7. , . Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500–1505.
8. , . Papanicolaou smears without endocervical cells: are they inadequate?Acta Cytol 1986;30:258.
9. , , , et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235–240.
10. , , , et al. Ultrastructural studies of spontaneously regressing plane warts: macrophages attack verruca-epidermal cells. Arch Dermatol Res 1981;270:403–411.
11. , , , et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–265.
12. . Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–17.
13. , . Unusual patterns of squamous epithelium of the uterine cervix: cytologic and pathologic study of koilocytotic atypia. Ann NY Acad Sci 1956;63:1235–1240.
14. , , . Condylomatous lesions of the cervix. 2. Cytologic, colposcopic and histopathologic study. Acta Ctyol 1977;21:379–390.
15. , . Papillomaviruses: In , , (eds.) Principles and Practice of Infectious Disease, 5th edn. Philadelphia, PA: Churchill Livingstone, 2000.
16. , , , et al. Humoral and cell-mediated immunity to human papillomavirus type 1 (HPV-1) in human warts. Br J Dermatol 1983;108:665–672.
17. , , , et al. Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol 1991;72:1343–1347.
18. , , , et al. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis. Virology 1992;188:384–387.
19. , , , et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
20. , , , et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485–490.
21. , , , et al. Human papillomavirus detection by hybrid capture in paired cervicovaginal lavage and cervical biopsy specimens. J Med Virol 1996;48:210–214.
22. , , , et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364–368.
23. , , , et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272–1278.
24. , , , et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871–1876.
26. , , , et al. Cervex-Brush and Cytobrush: comparison of their ability to sample abnormal cells for cervical smears. J Reprod Med 1991;36:581–586.
27. , , , et al. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet 1999;354:1763–1770.
28. . FDA clarifies labeling of liquid-based systems. Acta Cytol 2000;44:1120.
29. , , , et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167–170.
30. , , . Trends in self-reported use of mammograms (1989–1997) and Papanicolaou tests (1991–1997): Behavioral Risk Factor Surveillance System. MMWR CDC Surveill Summ 1999;48:1–22.
31. , , , et al. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528–1540.
32. , , . The National Breast and Cervical Cancer Early Detection Program: a comprehensive public health response to two major health issues for women. J Public Health Manag Pract 1996;2:36–47.
34. . Task Force recommendations. Ann Intern Med 2012;156:880–891.
35. , , , et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guideline for the Prevention and Early Detection of Cervical Cancer. CA Cancer J Clin 2012;62:147–172.
36. . ACOG Practice Bulletin No. 109: clinical management guidelines for obstetrician-gynecologists – cervical cytology screening. Obstet Gynecol 2012;20:1222–1238.
37. , , , et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757–1764.
38. , , , et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007:346–355.
39. , , , et al. Report of a national workshop on screening for cancer of the cervix. CMAJ 1991;145:1301–1325.
40. , , . The natural history of cancer of the cervix, and the implications for screening policy. In , , , et al. (eds.) Cancer Screening. Cambridge, UK: Cambridge University Press, 1991, pp. 144–152.
41. , . Practice Improvement in Cervical Screening and Management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Dis 2010:14:73–80.
42. . The (in)efficiency of cervical screening in Europe. Eur J Cancer 2002;38:321–326.
43. , , . Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88–93.
44. . Cervical Cancer Screening Programmes: Managerial Guidelines. Geneva: World Health Organization, 1992.
45. . Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986;293:659–664.
46. , . Basic issues in population screening for cancer. JNCI 1980;64:1263–1272.
47. , , . Optimising the age, number of tests, and the test interval for cervical screening in Canada. J Epidemiol Community Health 1982;36:1–10.
48. , . Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 1995;24:3007.
49. . Failures of cervical cancer screening. Am J Public Health 1995;85:761–762.
50. . Evidence for the existence of two forms of cervical carcinoma. J Obstet Gynaecol Br Commonw 1966;73:382–389.
51. , , , et al. Duration of relative protection of screening for cervical cancer. Prev Med 1989;18:411–422.
52. , , , et al. Relation between the incidence of invasive cervical cancer and the screening interval: is a five year interval too long?J Med Screen 1996;3:140–145.
53. , , , et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107–3115.
54. , , , et al. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol 2003;101:29–37.
55. , , , et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501–1509.
56. , , . Upper age limit for cervical cancer screening. Eur J Cancer 1996;32A:180.
57. , , , et al. European guidelines for quality assurance in cervical cancer screening: Europe Against Cancer Programme. Eur J Cancer 1993;29A(Suppl 4):S1–S38.
58. , , , et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
59. ., , . 2001 consensus guidelines for the management of women with cervical cytological abnormalities. J Lower Genital Tract Dis 2002;6:127–143.
60. , . Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. JNCI 2000;92:397–402.
61. , , , et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. JNCI Monogr 1996;21:17–25.
62. , , , et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727–735.
63. . The natural history of lower genital tract precancer: historical perspective. In , , (eds.) Lower Genital Tract Neoplasia. London: Royal College of Obstetricians and Gynaecologists, 2004, pp. 69–81.
64. , , , . Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999;93:359–362.
65. . ACOG Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol 2013;122:1338–1367.
66. , , , et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999;21:33–41.
67. , , , et al. The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women. Gynecol Oncol 1999;74:428–431.
68. , . Cancer death rates associated with human immunodeficiency virus infection in the United States. JNCI 1998;90:1300–1302.
69. , , . Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. JNCI 2000;92:1500–1510.
70. . Sexually transmitted diseases treatment guidelines 2010. MMWR 2010;59(RR-12):44–47.
71. , . Follow-up of abnormal gynecologic cytology: a college of American Pathologists Q-probes study of 16 132 cases from 306 laboratories. Arch Pathol Lab Med 2000;124:665–671.
72. , , , et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999;30:816–825.
73. , , , et al. Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. Obstet Gynecol 1998;91:278–282.
74. , , , et al. Neoplasia associated with atypical glandular cells of undetermined significance on cervical cytology. Gynecol Oncol 1997;65:314–318.
75. , , , et al. Endocervical glandular atypia in Papanicolaou smears. Obstet Gynecol 1992;79:101–104.
76. , , , et al. Atypical cervical cytology: colposcopic follow-up using the Bethesda system. J Reprod Med 1993;38:443–447.
77. , , , et al. The reliability of a cytological prediction of cervical adenocarcinoma in situ. Aust N Z J Obstet Gynaecol 1988;28:307–312.
78. , , . Atypical endocervical glandular cells: accuracy of cytologic diagnosis. Diagn Cytopathol 1995;71:894–897.
79. , , , et al. SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute, 2004.
80. , , , et al. Expanded cytologic criteria for the diagnosis of adenocarcinoma in situ of the cervix and related lesions. Acta Cytol 1980;24:283–296.
81. , , , . The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri and related lesions. 1. Adenocarcinoma in situ. Acta Cytol 1987;31:397–411.
82. , . Cervical intraepithelial glandular neoplasia (adenocarcinoma in situ and glandular dysplasia): a correlative study of 23 cases with histologic grading, histochemical analysis of mucins, and immunohistochemical determination of the affinity for four lectins. Cancer 1986;58:1272–1280.
83. , , . Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 1997;90:1–6.
84. , , , et al. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case–control study. Cancer Causes Control 1996;7:391–401.
85. , , , et al. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix, and coexisting cervical squamous intraepithelial neoplasia. Int J Gynecol Pathol 1989;8:8–17.
86. , , , et al. Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification. Int J Gynecol Pathol 1994;13:143–149.
87. , . Cervical crypt involvement by intraepithelial neoplasia. Am J Obstet Gynecol 1980;55:546–550.
88. , , . Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2000;(2):CD001318.
89. , , , et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:737.
90. , , . Endocervical gland involvement by cervical intraepithelial neoplasia grade III: predictive value for residual and/or recurrent disease. Cancer 1991;68:1932.
91. . Treatment of grade 3 cervical intraepithelial neoplasia. In , , , (eds.) Colposcopy Management Options. London: Saunders, 2003, pp. 129–135.
92. , , , et al. Follow up after LLETZ: could schedules be modified according to risk of recurrence?. Br J Obstet Gynaecol 2001;108:1025–1030.
93. , , , et al. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1997;104:718–722.
94. . The use of the carbon dioxide laser in the therapy of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1982;144:377–380.
95. . Cryosurgery for CIN. Obstet Gynecol Surv 1979;34:828.
96. , , . A comparison of complications of laser and cold knife conization. Obstet Gynecol 1983;62:213–217.
97. , , . A ten-year experience treating cervical intraepithelial neoplasia with CO2 laser. Am J Obstet Gynecol 1989;161:60–68.
98. , . Intraepithelial disease of the cervix, vagina and vulva. In , , (eds.) Novak's Gynecology, 12th edn. Baltimore, MD: Williams & Wilkins, 1996, pp. 447–474.
99. , , , et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet 2011;12:663.
100. , , , et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet 2010;11:249–257.
101. , , , et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589–1597.
102. , , , et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet 2007;370:1764–1772.
103. , , . Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;356:1579.
104. , , . Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619–631.
105. , . Patient preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol 1997;92:2171–2178.
106. , , . Evidence-based vs. emotion-based medical decision-making: routine preoperative HIV testing vs. universal precautions. J Clin Epidemiol 1993;46:1233–1236.
107. . Population-based mammographic screening: does “informed choice” require any less than full disclosure to individuals of benefits, harms, limitations, and consequences?Aust N Z J Public Health 1999;23:301–304.
108. , , . Women's understanding of a “normal smear test result”: experimental questionnaire based study. BMJ 2001;322:526–528.
109. , , , et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.